AIM ImmunoTech Inc. 于2026年7月31日签署了一份与 Sterling Pharma Solutions 的合作提案协议——该信息源自一份向美国证券交易委员会（SEC）提交的官方文件。
这一举动，标志着这家生物科技公司在研发及生产布局上迈出了关键性的一步。协议的具体条款与战略意图，在公开文件中得到了初步阐述。
双方的合作，旨在通过整合各自的技术与资源优势，推动相关药物候选物的临床前与临床进展。值得注意的是，Sterling Pharma Solutions 作为一家在药物开发与制造领域拥有深厚积淀的合约研究组织，其专业能力有望为 AIM ImmunoTech 的核心管线注入新的活力。
对于投资者而言，这份协议不仅意味着潜在的生产外包或联合开发机会，更可能预示着公司对旗下免疫疗法资产的商业化路径有了更清晰的规划。SEC 文件的正式披露，为市场提供了审视这一战略联盟的透明窗口。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.